Analyst bumps up price target on QDEL on back of “sweetened” deal to acquire Alere’s BNP Assay segment.
EXACT Sciences Corporation (NASDAQ:EXAS) shares fell almost 15% yesterday after the molecular diagnostics company posted third-quarter earnings yesterday. Yet, Canaccord analyst Mark Massaro …
In a research report issued Wednesday, Canaccord analyst Mark Massaro reiterated a Buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS), while reducing the …
Canaccord analyst Mark Massaro was out pounding the table on EXACT Sciences Corporation (NASDAQ:EXAS) Thursday, reiterating a Buy rating and price target of $26, …
In a research report published Monday, Canaccord analyst Mark Massaro maintained a Buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS) with a price target …
In a research report published yesterday, Canaccord analyst Mark Massaro maintained a Buy rating on shares of Illumina, Inc. (NASDAQ:ILMN), with a price target …
In a research report released today, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $32 price target, …
In a research report released this morning, Canaccord Genuity analyst Mark Massaro initiated coverage on shares of Illumina, Inc (NASDAQ:ILMN) with a Buy rating …
In a research report published today, Canaccord Genuity analyst Mark Massaro weighed in with some of his opinions on EXACT Sciences Corporation (NASDAQ:EXAS) following the …
Canaccord Genuity analyst Mark Massaro offered some commentary on EXACT Sciences Corporation (NASDAQ:EXAS) ahead of the company’s first ever Analyst Day, which will take …
